©The Author(s) 2015.
World J Gastroenterol. Nov 21, 2015; 21(43): 12410-12420
Published online Nov 21, 2015. doi: 10.3748/wjg.v21.i43.12410
Published online Nov 21, 2015. doi: 10.3748/wjg.v21.i43.12410
Table 2 Univariate analyses of factors related to overall survival
| Variable | Hazard ratio (95%CI) | P value | |
| Clinicopathological factors | |||
| Age (yr) | < 65 vs≥ 65 | 1.295 (0.922-1.821) | 0.136 |
| Sex | Female vs male | 0.897 (0.653-1.233) | 0.504 |
| ECOG-PS | 0-1 vs 2-4 | 1.528 (1.107-2.109) | 0.010 |
| Tumor site | Colon vs rectum | 0.823 (0.575-1.177) | 0.286 |
| Liver metastasis | No vs yes | 1.469 (1.056-2.044) | 0.023 |
| Prior surgery | No vs yes | 0.797 (0.525-1.211) | 0.288 |
| Prior chemotherapy | None vs 1st or 2nd line | 0.670 (0.392-1.145) | 0.143 |
| None vs≥ 3rd line | 0.897 (0.526-1.529) | 0.689 | |
| Prior radiotherapy | No vs yes | 0.991 (0.698-1.409) | 0.962 |
| BMI (kg/m2) | < 18.5 vs 18.5-22.9 | 0.697 (0.425-1.144) | 0.154 |
| < 18.5 vs≥ 23 | 0.700 (0.420-1.169) | 0.173 | |
| KM treatment duration (mo) | ≥ 2.9 vs < 2.9 | 1.966 (1.425-2.711) | < 0.001 |
| Laboratory factors | |||
| CEA (ng/mL) | ≤ 5 vs > 5 | 1.576 (1.016-2.444) | 0.042 |
| CA19-9 (U/mL) | ≤ 27 vs > 27 | 1.654 (1.139-2.402) | 0.008 |
| Hb (g/dL) | > 12.1 vs ≤ 12.1 | 1.721 (1.246-2.378) | 0.001 |
| AST (IU/L) | < 40 vs≥ 40 | 2.547 (1.678-3.867) | < 0.001 |
| ALT (IU/L) | < 40 vs≥ 40 | 1.845 (1.139-2.991) | 0.013 |
| eGFR (mL/min) | ≥ 60 vs < 60 | 0.942 (0.634-1.399) | 0.766 |
| albumin (g/dL) | ≥ 3.5 vs < 3.5 | 2.202 (1.214-3.993) | 0.009 |
| CRP (mg/L) | < 10.0 vs≥ 10.0 | 2.202 (1.577-3.076) | < 0.001 |
| PLT (× 103/μL) | < 400 vs≥ 400 | 0.618 (0.367-1.042) | 0.071 |
| WBC (× 103/μL) | < 10.0 vs≥ 10.0 | 1.595 (0.945-2.691) | 0.080 |
| Neutrophil (%) | ≤ 68.2 vs > 68.2 | 1.576 (1.146-2.168) | 0.005 |
| Lymphocyte (%) | > 24.3 vs ≤ 24.3 | 1.923 (1.369-2.700) | < 0.001 |
| Monocyte (%) | ≤ 6.6 vs > 6.6 | 1.316 (0.931-1.860) | 0.120 |
| ANC (cells/μL) | ≤ 4505.7 vs > 4505.7 | 1.832 (1.328-2.527) | < 0.001 |
| ALC (cells/μL) | ≤ 1651.3 vs > 1651.3 | 0.779 (0.549-1.107) | 0.164 |
| AMC (cells/μL) | ≤ 460.8 vs > 460.8 | 1.830 (1.325-2.527) | < 0.001 |
| Systemic inflammation markers | |||
| mGPS | 0 vs 1 | 1.998 (1.403-2.844) | < 0.001 |
| 0 vs 2 | 4.741 (2.418-9.297) | < 0.001 | |
| NLR | < 5 vs≥ 5 | 2.388 (1.609-3.545) | < 0.001 |
| PLR | < 150 vs 150-300 | 1.204 (0.849-1.708) | 0.297 |
| < 150 vs > 300 | 1.989 (1.253-3.157) | 0.004 | |
| LMR | > 3.4 vs ≤ 3.4 | 2.045 (1.450-2.884) | < 0.001 |
| PNI | > 45.3 vs ≤ 45.3 | 1.785 (1.271-2.507) | 0.001 |
- Citation: Song A, Eo W, Lee S. Comparison of selected inflammation-based prognostic markers in relapsed or refractory metastatic colorectal cancer patients. World J Gastroenterol 2015; 21(43): 12410-12420
- URL: https://www.wjgnet.com/1007-9327/full/v21/i43/12410.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i43.12410